Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
Abstract
Sequential combination of immunogenic cell death (ICD)-induced interventions with subsequent immunotherapy has shown efficacy in preclinical models and clinical evaluation. Recently, a clinical trial enrolling small cell lung cancer patients treated with amrubicin together with PD-1 blockade confirmed the notion that ICD sensitizes tumors to immune checkpoint inhibitors.
Domains
Cancer
Fichier principal
Small cell lung cancer responds to immunogenic chemotherapy followed by PD 1 blockade.pdf (806.72 Ko)
Télécharger le fichier
| Origin | Publication funded by an institution |
|---|